ALPINE IMMUNE SCIENCES INC NVLS
COM · Common Stock · CUSIP 02083G100
0
institutional holders
-181 vs Q1 2024
—reported value*
0 new
0 added
0 reduced
177 sold out
net sold ≈ $2.6bn (-66.1m shares)
* Summed across managers. Shares that two managers' reports both contain – a subsidiary's holdings that its parent's report includes too, or a sub-adviser's in its client's – are counted once. Holder counts are more reliable.
Trends to Q2 2024
Institutional holders
Managers reporting a position, each quarter
Numbers
| Quarter | Holders |
|---|---|
| Q3 2022 | 70 |
| Q4 2022 | 64 |
| Q1 2023 | 61 |
| Q2 2023 | 77 |
| Q3 2023 | 89 |
| Q4 2023 | 134 |
| Q1 2024 | 181 |
| Q2 2024 | 0 |
Buyers vs sellers
Managers adding to or starting a position, vs cutting or selling out
Bought or addedCut or sold out
Numbers
| Quarter | Bought or added | Cut or sold out |
|---|---|---|
| Q4 2022 | 40 | 24 |
| Q1 2023 | 31 | 20 |
| Q2 2023 | 52 | 14 |
| Q3 2023 | 51 | 26 |
| Q4 2023 | 109 | 19 |
| Q1 2024 | 128 | 57 |
| Q2 2024 | 0 | 177 |
Calls vs puts
Options held, notional value, last 4 quarters. P/C = puts ÷ calls
CallsPuts
Numbers
| Quarter | Calls | Puts | P/C |
|---|---|---|---|
| Q3 2023 | $20.6k | $0 | 0.00 |
| Q4 2023 | $140.1k | $24.8k | 0.18 |
| Q1 2024 | $6.3m | $11.8m | 1.88 |
| Q2 2024 | $0 | $0 | — |
Biggest buyers
| None |
Biggest sellers
| Decheng Capital LLC | Sold out | -8.3m |
| Avoro Capital Advisors LLC | Sold out | -5.8m |
| BlackRock Inc. | Sold out | -3.6m |
| Frazier Life Sciences Management, L.P. | Sold out | -3.1m |
| PRICE T ROWE ASSOCIATES INC /MD/ | Sold out | -3.1m |
| STATE STREET CORP | Sold out | -2.8m |
| VANGUARD GROUP INC | Sold out | -2.7m |
| Cormorant Asset Management, LP | Sold out | -2.7m |
| ORBIMED ADVISORS LLC | Sold out | -2.7m |
| MORGAN STANLEY | Sold out | -2.4m |
Holders, Q2 2024
| Manager | Shares | Change |
|---|